ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced additional positive results from a recent study that evaluated its lead anti-influenza drug, Homspera®, in ferrets. Performed at a public University under the guidance of a world-renowned influenza expert, the study utilized a ‘real-world’ scenario of highly pathogenic influenza infection by a clade 2.2 H5N1 virus (A/Whooperswan/Mongolia/244/2005), and drug treatment beginning one day following influenza infection, coinciding with emergence of the first symptoms…

The rest is here: 
ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza

You may also like:

• Glycyrrhizin Extracted From Licorice Root Helps The Body Defend Against Pseudomonas Aeruginosa Infection Following Severe Burns
• New Epigenetic Study Shows A Link Between Maternal Diet And Brain Development In Gestating Mice
• NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia
• BioAlliance Pharma: Breakthrough Positive Phase III Results With Acyclovir Lauriad(R) Primary And Secondary Endpoints Met - Final Results
• Physicists Find Clues To The Origin And Evolution Of Wrinkles
• Subchondral Bone Changes Contribute To Cartilage Damage And Loss
• Using CT Scans To Study Severe Asthma
• ER Computer Keyboards And Bacteria
• Novartis Phase III Trial Examining EPO906 (patupilone) For Patients With Advanced Ovarian Cancer Failed To Meet Primary Endpoint
• More Left-Side Skin Cancer, SLU Researcher Finds